Measles seroprevalence and vaccine response in HIV-infected adults.
Measles in HIV-infected patients can be a severe, even fatal, illness. The prevalence of measles seropositivity in HIV-infected adults and the durability of these antibody levels are uncertain. A prospective survey of 210 HIV-infected adults found that 95% of the adults had demonstrable antibodies using a standard ELISA technique. Seropositivity was no different in patients with CD4 counts over 400, from those with more advanced disease and CD4 counts under 200 (p = 0.8). Six seronegative patients were vaccinated and had serial antibody determinations: two of six (33%) patients had a durable positive antibody response at 1 year, and none had any observed toxicity. Vaccination of the identified measles-seronegative HIV-infected adults who are at high risk for measles is recommended, but a measurable antibody response may be expected in only a minority of cases.
Wallace
M R
MR
Department of Internal Medicine (HIV Division), Naval Medical Center, San Diego.
Hooper
D G
DG
Graves
S J
SJ
Malone
J L
JL
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000276:immunology*; D006801:Humans; D008297:Male; D008457:Measles / Q000150:complications / Q000276:immunology / Q000517:prevention & control; D008458:Measles Vaccine / Q000276:immunology / Q000494:pharmacology*; D008459:Measles virus / Q000276:immunology*; D011446:Prospective Studies
D000914:Antibodies, Viral; D008458:Measles Vaccine